HK1254957A1 - 作为有效的hno供体的具有碳基离去基团的n-取代的异羟肟酸及其用途 - Google Patents
作为有效的hno供体的具有碳基离去基团的n-取代的异羟肟酸及其用途 Download PDFInfo
- Publication number
- HK1254957A1 HK1254957A1 HK18114062.4A HK18114062A HK1254957A1 HK 1254957 A1 HK1254957 A1 HK 1254957A1 HK 18114062 A HK18114062 A HK 18114062A HK 1254957 A1 HK1254957 A1 HK 1254957A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- efficient
- carbon
- leaving groups
- hydroxamic acids
- substituted hydroxamic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/50—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185310P | 2015-06-26 | 2015-06-26 | |
| US62/185,310 | 2015-06-26 | ||
| PCT/US2016/039453 WO2016210392A1 (en) | 2015-06-26 | 2016-06-25 | N-substituted hydroxamic acids with carbon-based leaving groups as efficient hno donors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1254957A1 true HK1254957A1 (zh) | 2019-08-02 |
Family
ID=56409199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18114062.4A HK1254957A1 (zh) | 2015-06-26 | 2016-06-25 | 作为有效的hno供体的具有碳基离去基团的n-取代的异羟肟酸及其用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10583141B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3313831B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6820015B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107922371B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2871079T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1254957A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016210392A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10723704B2 (en) | 2015-10-19 | 2020-07-28 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| US10730828B2 (en) | 2015-10-19 | 2020-08-04 | Cardioxyl Pharmaceuticals, Inc. | N-hydroxylsulfonamide derivatives as nitroxyl donors |
| KR20190070912A (ko) * | 2016-07-28 | 2019-06-21 | 더 존스 홉킨스 유니버시티 | O-치환된 히드록삼산 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007227457B2 (en) * | 2006-03-17 | 2013-03-28 | Cardioxyl Pharmaceuticals, Inc. | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| IN2012DN05028A (cg-RX-API-DMAC7.html) | 2009-12-07 | 2015-10-23 | Univ Johns Hopkins | |
| CA2782110A1 (en) | 2009-12-07 | 2011-06-16 | Johns Hopkins University | N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives |
| CN108409662B (zh) * | 2011-10-17 | 2021-10-26 | 约翰斯霍普金斯大学 | 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物 |
| EP3148972B1 (en) * | 2014-05-27 | 2019-08-21 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| WO2015183838A1 (en) * | 2014-05-27 | 2015-12-03 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives as nitroxyl donors |
-
2016
- 2016-06-25 EP EP16738303.3A patent/EP3313831B1/en active Active
- 2016-06-25 ES ES16738303T patent/ES2871079T3/es active Active
- 2016-06-25 JP JP2017567124A patent/JP6820015B2/ja active Active
- 2016-06-25 US US15/738,932 patent/US10583141B2/en active Active
- 2016-06-25 CN CN201680048966.XA patent/CN107922371B/zh not_active Expired - Fee Related
- 2016-06-25 WO PCT/US2016/039453 patent/WO2016210392A1/en not_active Ceased
- 2016-06-25 HK HK18114062.4A patent/HK1254957A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018520145A (ja) | 2018-07-26 |
| CN107922371A (zh) | 2018-04-17 |
| US20180185367A1 (en) | 2018-07-05 |
| WO2016210392A1 (en) | 2016-12-29 |
| JP6820015B2 (ja) | 2021-01-27 |
| EP3313831A1 (en) | 2018-05-02 |
| EP3313831B1 (en) | 2021-03-10 |
| US10583141B2 (en) | 2020-03-10 |
| CN107922371B (zh) | 2022-04-19 |
| ES2871079T3 (es) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016065349A8 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
| EP3507367A4 (en) | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF | |
| WO2016044463A3 (en) | Mk2 inhibitors and uses thereof | |
| EP3234200A4 (en) | Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins | |
| MX2022009148A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| EP4410805A3 (en) | Raav-based compositions and methods for treating amyotrophic lateral sclerosis | |
| WO2015196128A3 (en) | Alternative nucleic acid molecules and uses thereof | |
| WO2015196130A3 (en) | Alternative nucleic acid molecules and uses thereof | |
| EP3292116B8 (en) | 3-aryl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors | |
| MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
| HK1216859A1 (zh) | Irak抑制劑和其用途 | |
| WO2018006074A3 (en) | Compounds and methods for modulating rna function | |
| EP3313989A4 (en) | Modified crispr rna and modified single crispr rna and uses thereof | |
| CA3306297A1 (en) | Secukinumab compositions, uses and kits thereof, and processes for stabilizing antibody formulations | |
| EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
| EP4524255A3 (en) | Methods and compositions for nucleic acid analysis | |
| MX2018006288A (es) | Inhibidores de acc tipo ester y usos de los mismos. | |
| EP4112611A3 (en) | Modulators of sestrin-gator2 interaction and uses thereof | |
| MX382276B (es) | Recubrimientos acuosos de fijado rápido. | |
| WO2015077657A3 (en) | Stat3 inhibitors and uses thereof | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| WO2015191945A3 (en) | Solid state forms of sofosbuvir | |
| EP4218736A3 (en) | Compositions comprising 15-hepe | |
| EP3259350A4 (en) | Multi-domain enzymes having cutinase activity, compositions comprising same and uses thereof | |
| EP3256592A4 (en) | Compositions and methods for modulating rna |